{"id":"tiragolumab-and-atezolizumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Cough"},{"rate":"10-20%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tiragolumab and atezolizumab work by blocking the interaction between TIGIT and its ligands, and PD-L1 and its receptor PD-1, respectively, which can help to restore the body's immune response against cancer cells. This can lead to the activation of immune cells, such as T cells, which can then attack and kill cancer cells. By targeting these immune checkpoints, tiragolumab and atezolizumab can help to enhance the body's anti-tumor immune response.","oneSentence":"Tiragolumab is a monoclonal antibody that targets TIGIT, while atezolizumab is a monoclonal antibody that targets PD-L1, both of which are involved in immune checkpoint inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:59.148Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT05286801","phase":"PHASE1, PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":"Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma","enrollment":86},{"nctId":"NCT06713798","phase":"PHASE2","title":"Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures","status":"WITHDRAWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-01-30","conditions":"Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer","enrollment":""},{"nctId":"NCT05862285","phase":"PHASE3","title":"A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-01","conditions":"Cancer","enrollment":100},{"nctId":"NCT04300647","phase":"PHASE2","title":"A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-30","conditions":"Cervical Cancer","enrollment":172},{"nctId":"NCT04832854","phase":"PHASE2","title":"A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-04-23","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":50},{"nctId":"NCT04929223","phase":"PHASE1","title":"A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-22","conditions":"Metastatic Colorectal Cancer","enrollment":542},{"nctId":"NCT05681039","phase":"PHASE2","title":"Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-06-02","conditions":"Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma","enrollment":29},{"nctId":"NCT06760481","phase":"PHASE1","title":"Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-04-13","conditions":"Advanced Solid Malignancies","enrollment":7},{"nctId":"NCT06603818","phase":"PHASE2","title":"Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-08-15","conditions":"Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer","enrollment":""},{"nctId":"NCT06754501","phase":"PHASE2","title":"A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-04-11","conditions":"Cancer","enrollment":4},{"nctId":"NCT04665856","phase":"PHASE3","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-12-21","conditions":"Small Cell Lung Carcinoma","enrollment":123},{"nctId":"NCT05661578","phase":"PHASE2","title":"A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-05-04","conditions":"PD-L1-selected Solid Tumors","enrollment":64},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":"Triple Negative Breast Cancer","enrollment":81},{"nctId":"NCT03784326","phase":"PHASE2","title":"Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-02-19","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8","enrollment":43},{"nctId":"NCT04619797","phase":"PHASE2, PHASE3","title":"A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-12-15","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":542},{"nctId":"NCT06267001","phase":"PHASE3","title":"A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2024-03-21","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":56},{"nctId":"NCT05645692","phase":"PHASE2","title":"A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-04-13","conditions":"Urothelial Cancer","enrollment":204},{"nctId":"NCT04256421","phase":"PHASE3","title":"A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-04","conditions":"Small Cell Lung Cancer","enrollment":490},{"nctId":"NCT04958811","phase":"PHASE2","title":"Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2021-12-21","conditions":"Non-squamous Non-small-cell Lung Cancer","enrollment":29},{"nctId":"NCT05009069","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-18","conditions":"Rectal Neoplasms, Rectal Cancer","enrollment":58},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT05746481","phase":"PHASE2","title":"Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","status":"TERMINATED","sponsor":"Liza Villaruz, MD","startDate":"2023-08-10","conditions":"Non-small Cell Lung Cancer","enrollment":3},{"nctId":"NCT04543617","phase":"PHASE3","title":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-09-28","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":760},{"nctId":"NCT03563716","phase":"PHASE2","title":"A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2018-08-10","conditions":"Non-small Cell Lung Cancer","enrollment":135},{"nctId":"NCT05904886","phase":"PHASE3","title":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-14","conditions":"Hepatocellular Carcinoma","enrollment":687},{"nctId":"NCT03554083","phase":"PHASE2","title":"Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-10-05","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","enrollment":59},{"nctId":"NCT03281369","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-13","conditions":"Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","enrollment":214},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT05908786","phase":"PHASE1, PHASE2","title":"A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-12-05","conditions":"Carcinoma, Hepatocellular","enrollment":62},{"nctId":"NCT05715281","phase":"PHASE2","title":"Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-09-26","conditions":"Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm","enrollment":12},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT04540211","phase":"PHASE3","title":"A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-30","conditions":"Esophageal Cancer","enrollment":461},{"nctId":"NCT05251948","phase":"PHASE1, PHASE2","title":"An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-03-01","conditions":"Gastric and Gastroesophageal Junction Carcinoma","enrollment":40},{"nctId":"NCT06784947","phase":"PHASE2","title":"Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-03-25","conditions":"Microsatellite Stable (MSS) Colorectal Cancer (CRC), Metastatic Colorectal Cancer (CRC), Colorectal Cancer Stage IV","enrollment":13},{"nctId":"NCT05798663","phase":"PHASE2","title":"Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2023-12-07","conditions":"NSCLC","enrollment":178},{"nctId":"NCT04665843","phase":"PHASE2","title":"A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":123},{"nctId":"NCT05459129","phase":"PHASE1, PHASE2","title":"A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-12","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":12},{"nctId":"NCT04513925","phase":"PHASE3","title":"A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-08-24","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":829},{"nctId":"NCT04486352","phase":"PHASE1, PHASE2","title":"A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-10-20","conditions":"Endometrial Cancer","enrollment":148},{"nctId":"NCT03977467","phase":"PHASE2","title":"Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2019-08-30","conditions":"Non-Small Cell Lung Cancer, Solid Tumor","enrollment":46},{"nctId":"NCT06762808","phase":"PHASE2","title":"Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-05-01","conditions":"Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT05116202","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-02-02","conditions":"Melanoma","enrollment":110},{"nctId":"NCT05825625","phase":"PHASE2","title":"NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-05-26","conditions":"Non-small Cell Lung Cancer","enrollment":35},{"nctId":"NCT05483400","phase":"PHASE2","title":"Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2023-10-18","conditions":"Head and Neck Neoplasms, MSI-H Cancer, Melanoma","enrollment":97},{"nctId":"NCT03708224","phase":"PHASE2","title":"Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck","status":"RECRUITING","sponsor":"Alain Algazi","startDate":"2019-03-08","conditions":"Cancer, Carcinoma, Squamous Cell Carcinoma","enrollment":55},{"nctId":"NCT04632992","phase":"PHASE2","title":"A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2021-01-13","conditions":"Advanced Unresectable or Metastatic Solid Malignancy","enrollment":252},{"nctId":"NCT06328036","phase":"PHASE2","title":"Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2025-04-30","conditions":"Recurrent Glioblastoma, IDH-Wildtype","enrollment":""},{"nctId":"NCT06331598","phase":"PHASE2","title":"A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2024-11-30","conditions":"Solid Tumors","enrollment":""},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT06003621","phase":"PHASE2","title":"Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients","status":"RECRUITING","sponsor":"Omico","startDate":"2023-12-15","conditions":"Solid Tumor, Adult","enrollment":96},{"nctId":"NCT04933227","phase":"PHASE2","title":"A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-08-06","conditions":"Stomach Neoplasms, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":29},{"nctId":"NCT05315713","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-10","conditions":"Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":8},{"nctId":"NCT06342037","phase":"PHASE2","title":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-06-12","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT05060003","phase":"PHASE2","title":"Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2022-11-08","conditions":"Stage II Melanoma","enrollment":7},{"nctId":"NCT05743504","phase":"PHASE1, PHASE2","title":"Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-09-18","conditions":"Locally Advanced Esophageal Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT04308785","phase":"PHASE2","title":"A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2021-12-01","conditions":"Carcinoma, Small Cell Lung","enrollment":24},{"nctId":"NCT05259319","phase":"PHASE1","title":"Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)","status":"UNKNOWN","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-12-05","conditions":"Metastatic Non Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Renal Cell Carcinoma","enrollment":92},{"nctId":"NCT05661188","phase":"PHASE2","title":"Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)","status":"RECRUITING","sponsor":"Grupo Espanol Multidisciplinario del Cancer Digestivo","startDate":"2023-02-14","conditions":"Squamous Cell Carcinoma of the Anal Canal","enrollment":45},{"nctId":"NCT04045028","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2019-07-22","conditions":"Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma","enrollment":41},{"nctId":"NCT04584112","phase":"PHASE1","title":"A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-28","conditions":"Triple-Negative Breast Cancer","enrollment":83},{"nctId":"NCT05034055","phase":"PHASE2","title":"Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2021-12","conditions":"Non-small Cell Lung Cancer","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RO7538483"],"phase":"phase_3","status":"active","brandName":"Tiragolumab and atezolizumab","genericName":"Tiragolumab and atezolizumab","companyName":"University Medical Center Groningen","companyId":"university-medical-center-groningen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tiragolumab is a monoclonal antibody that targets TIGIT, while atezolizumab is a monoclonal antibody that targets PD-L1, both of which are involved in immune checkpoint inhibition. Used for Non-small cell lung cancer, Renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}